Affinia Therapeutics Inc. has obtained IND clearance from the FDA for AFTX-201, an investigational genetic medicine for the ...

The BioWorld Cancer Index closed 2025 up 72.35%, outpacing gains in the Nasdaq Biotechnology Index (up 32.4%) and the Dow ...

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it ...

Trumprx.gov launched with much fanfare late Feb. 5, and the online tool brings promise for the “world’s lowest prices” on prescription drugs. Alongside the website hoopla came word from Hims & Hers ...

DNA polymerase θ (POLθ) is a specialized, error-prone DNA polymerase that promotes the repair of DNA double-strand breaks through theta-mediated end joining (TMEJ), an alternative pathway that ...

Third Arc Bio Inc. has closed a $52 million series A extension to advance its pipeline of multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications.

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Ayrmid, Biodexa, Biomica, DT Cloud Star, Entera, Evogene, Invacare, Lishan, Opko, Otsuka, Primegen, T2 ...

Biodexa Pharmaceuticals plc has closed an exclusive license agreement with Otsuka Pharmaceutical Co. Ltd. for OPB-171775 (now MTX-240), a phase I-ready molecular glue intended to be developed for the ...

After raising $61 million in a series B round, Vibrant Therapeutics Inc. is gearing up to begin a U.S. phase I trial with its lead program, VIB-305, a masked T-cell engager (TCE) for treating ...

Effective targeted therapies against aggressive breast cancer subtypes, such as triple-negative breast cancer (TNBC), are still lacking. Developing therapeutics targeting nonenzymatic, intracellular ...

In keeping with the congressional practice of passing major NIH reform legislation every 10 years, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee took the first step in looking ...

Pricing the third and largest biopharma IPO of 2026, Eikon Therapeutics Inc. raised $381 million in an upsized offering of 21.18 million shares of common stock at $18 each, the high point of its price ...